-transparent.png){kind=logo}
Tocainide, a congener of lidocaine, was used to treat symptomatic ventricular arrhythmias in 19 patients resistant to or unable to tolerate conventional agents. In this highly selected group, 15 showed good initial responses to oral therapy. Ventricular tachycardia was suppressed to a greater extent than isolated ventricular ectopic depolarizations at any plasma concentration, and upward dose-ranging showed progressive suppression of both. Arrhythmia responsiveness to lidocaine was found to be an excellent predictor of tocainide response. Of the 15 responders, one died 24 hours after stopping therapy, three died while receiving tocainide, nine stopped because of adverse reactions (five allergic), and two continue on therapy at 1 and 4 years. We conclude that tocainide is an effective agent for the short-term suppression of ventricular arrhythmias, particularly ventricular tachycardia sensitive to lidocaine, but a high incidence of adverse effects limits its application to chronic therapy in many patients.
D M Roden, and
D M Roden, and
S B Reele, and
S B Reele, and
S B Higgins, and
S B Higgins, and
R K Carr, and
R K Carr, and
R F Smith, and
R F Smith, and
J A Oates, and
J A Oates, and
R L Woosley, and
R L Woosley
April 1982,
The American journal of cardiology,
D M Roden, and
D M Roden, and
S B Reele, and
S B Reele, and
S B Higgins, and
S B Higgins, and
R K Carr, and
R K Carr, and
R F Smith, and
R F Smith, and
J A Oates, and
J A Oates, and
R L Woosley, and
R L Woosley
February 1983,
Clinical cardiology,
D M Roden, and
D M Roden, and
S B Reele, and
S B Reele, and
S B Higgins, and
S B Higgins, and
R K Carr, and
R K Carr, and
R F Smith, and
R F Smith, and
J A Oates, and
J A Oates, and
R L Woosley, and
R L Woosley
December 1980,
American heart journal,
D M Roden, and
D M Roden, and
S B Reele, and
S B Reele, and
S B Higgins, and
S B Higgins, and
R K Carr, and
R K Carr, and
R F Smith, and
R F Smith, and
J A Oates, and
J A Oates, and
R L Woosley, and
R L Woosley
May 1978,
Circulation,
D M Roden, and
D M Roden, and
S B Reele, and
S B Reele, and
S B Higgins, and
S B Higgins, and
R K Carr, and
R K Carr, and
R F Smith, and
R F Smith, and
J A Oates, and
J A Oates, and
R L Woosley, and
R L Woosley
April 1985,
The Nurse practitioner,
D M Roden, and
D M Roden, and
S B Reele, and
S B Reele, and
S B Higgins, and
S B Higgins, and
R K Carr, and
R K Carr, and
R F Smith, and
R F Smith, and
J A Oates, and
J A Oates, and
R L Woosley, and
R L Woosley
January 1986,
American family physician,
D M Roden, and
D M Roden, and
S B Reele, and
S B Reele, and
S B Higgins, and
S B Higgins, and
R K Carr, and
R K Carr, and
R F Smith, and
R F Smith, and
J A Oates, and
J A Oates, and
R L Woosley, and
R L Woosley
January 2020,
Annual review of medicine,
D M Roden, and
D M Roden, and
S B Reele, and
S B Reele, and
S B Higgins, and
S B Higgins, and
R K Carr, and
R K Carr, and
R F Smith, and
R F Smith, and
J A Oates, and
J A Oates, and
R L Woosley, and
R L Woosley
February 1985,
The Medical letter on drugs and therapeutics,
D M Roden, and
D M Roden, and
S B Reele, and
S B Reele, and
S B Higgins, and
S B Higgins, and
R K Carr, and
R K Carr, and
R F Smith, and
R F Smith, and
J A Oates, and
J A Oates, and
R L Woosley, and
R L Woosley
December 1980,
American heart journal,
D M Roden, and
D M Roden, and
S B Reele, and
S B Reele, and
S B Higgins, and
S B Higgins, and
R K Carr, and
R K Carr, and
R F Smith, and
R F Smith, and
J A Oates, and
J A Oates, and
R L Woosley, and
R L Woosley
December 1980,
American heart journal,
